skip to content
Creating Markets for New Vaccines Part I : Rationale Preview this item
ClosePreview this item
Checking...

Creating Markets for New Vaccines Part I : Rationale

Author: Michael Kremer
Publisher: Cambridge, Mass. National Bureau of Economic Research 2000.
Series: Working paper series (National Bureau of Economic Research), no. w7716.
Edition/Format:   eBook : Document : EnglishView all editions and formats
Summary:
Malaria, tuberculosis, and the strains of HIV common in Africa kill approximately 5 million people each year. Yet research on vaccines for these diseases remains minimal largely because potential vaccine developers fear that they would not be able to sell enough vaccine at a sufficient price to recoup their research expenditures. Enhancing markets for new vaccines could create incentives for vaccine research and  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Michael Kremer
OCLC Number: 1027299372
Notes: May 2000.
Description: 1 online resource.
Series Title: Working paper series (National Bureau of Economic Research), no. w7716.
Responsibility: Michael Kremer.

Abstract:

Malaria, tuberculosis, and the strains of HIV common in Africa kill approximately 5 million people each year. Yet research on vaccines for these diseases remains minimal largely because potential vaccine developers fear that they would not be able to sell enough vaccine at a sufficient price to recoup their research expenditures. Enhancing markets for new vaccines could create incentives for vaccine research and increase accessibility of any vaccines developed. Private firms currently conduct little research on vaccines against malaria, tuberculosis, and the strains of HIV common in Africa. This is not only because these diseases primarily affect poor countries, but also because vaccines are subject to severe market failures. Government- directed research programs may be well-suited for basic research, but for the later, more applied states of research, committing to compensate successful private vaccine developers has important advantages. Under such programs, the public pays only if a successful vaccine is actually developed. This gives pharmaceutical firms and scientists strong incentives to self-select research projects that have a reasonable chance of leading to a vaccine. Committing to purchase vaccines and make them available to poor countries may also be attractive relative to other ways of rewarding vaccine developers.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/1027299372> # Creating Markets for New Vaccines Part I : Rationale
    a schema:MediaObject, schema:CreativeWork, schema:Book ;
    library:oclcnum "1027299372" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/mau> ;
    library:placeOfPublication <http://experiment.worldcat.org/entity/work/data/144396839#Place/cambridge_mass> ; # Cambridge, Mass.
    schema:about <http://experiment.worldcat.org/entity/work/data/144396839#Topic/medical_assistance_economic_aspects_developing_countries> ; # Medical assistance--Economic aspects--Developing countries
    schema:about <http://experiment.worldcat.org/entity/work/data/144396839#Topic/vaccines_prices_government_policy> ; # Vaccines--Prices--Government policy
    schema:about <http://experiment.worldcat.org/entity/work/data/144396839#Place/developing_countries> ; # Developing countries.
    schema:about <http://experiment.worldcat.org/entity/work/data/144396839#Topic/vaccines_industry_government_policy> ; # Vaccines industry--Government policy
    schema:about <http://experiment.worldcat.org/entity/work/data/144396839#Topic/vaccines_research_economic_aspects> ; # Vaccines--Research--Economic aspects
    schema:bookFormat schema:EBook ;
    schema:creator <http://experiment.worldcat.org/entity/work/data/144396839#Person/kremer_michael_1964> ; # Michael Kremer
    schema:datePublished "2000" ;
    schema:description "Malaria, tuberculosis, and the strains of HIV common in Africa kill approximately 5 million people each year. Yet research on vaccines for these diseases remains minimal largely because potential vaccine developers fear that they would not be able to sell enough vaccine at a sufficient price to recoup their research expenditures. Enhancing markets for new vaccines could create incentives for vaccine research and increase accessibility of any vaccines developed. Private firms currently conduct little research on vaccines against malaria, tuberculosis, and the strains of HIV common in Africa. This is not only because these diseases primarily affect poor countries, but also because vaccines are subject to severe market failures. Government- directed research programs may be well-suited for basic research, but for the later, more applied states of research, committing to compensate successful private vaccine developers has important advantages. Under such programs, the public pays only if a successful vaccine is actually developed. This gives pharmaceutical firms and scientists strong incentives to self-select research projects that have a reasonable chance of leading to a vaccine. Committing to purchase vaccines and make them available to poor countries may also be attractive relative to other ways of rewarding vaccine developers."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/144396839> ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/144396839#Series/working_paper_series_national_bureau_of_economic_research> ; # Working paper series (National Bureau of Economic Research) ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/144396839#Series/nber_working_paper_series> ; # NBER working paper series
    schema:name "Creating Markets for New Vaccines Part I : Rationale"@en ;
    schema:productID "1027299372" ;
    schema:publication <http://www.worldcat.org/title/-/oclc/1027299372#PublicationEvent/cambridge_mass_national_bureau_of_economic_research2000> ;
    schema:publisher <http://experiment.worldcat.org/entity/work/data/144396839#Agent/national_bureau_of_economic_research> ; # National Bureau of Economic Research
    schema:url <http://www.nber.org/papers/w7716> ;
    schema:url <http://www.library.yorku.ca/e/resolver/id/1963594> ;
    schema:url <http://papers.nber.org/papers/w7716> ;
    schema:url <https://login.ezproxy.brunel.ac.uk/login?url=http://www.nber.org/papers/w7716> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/1027299372> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/144396839#Agent/national_bureau_of_economic_research> # National Bureau of Economic Research
    a bgn:Agent ;
    schema:name "National Bureau of Economic Research" ;
    .

<http://experiment.worldcat.org/entity/work/data/144396839#Person/kremer_michael_1964> # Michael Kremer
    a schema:Person ;
    schema:birthDate "1964" ;
    schema:familyName "Kremer" ;
    schema:givenName "Michael" ;
    schema:name "Michael Kremer" ;
    .

<http://experiment.worldcat.org/entity/work/data/144396839#Place/cambridge_mass> # Cambridge, Mass.
    a schema:Place ;
    schema:name "Cambridge, Mass." ;
    .

<http://experiment.worldcat.org/entity/work/data/144396839#Place/developing_countries> # Developing countries.
    a schema:Place ;
    schema:name "Developing countries." ;
    .

<http://experiment.worldcat.org/entity/work/data/144396839#Series/nber_working_paper_series> # NBER working paper series
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1027299372> ; # Creating Markets for New Vaccines Part I : Rationale
    schema:name "NBER working paper series" ;
    .

<http://experiment.worldcat.org/entity/work/data/144396839#Series/working_paper_series_national_bureau_of_economic_research> # Working paper series (National Bureau of Economic Research) ;
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1027299372> ; # Creating Markets for New Vaccines Part I : Rationale
    schema:name "Working paper series (National Bureau of Economic Research) ;" ;
    .

<http://experiment.worldcat.org/entity/work/data/144396839#Topic/medical_assistance_economic_aspects_developing_countries> # Medical assistance--Economic aspects--Developing countries
    a schema:Intangible ;
    schema:name "Medical assistance--Economic aspects--Developing countries"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/144396839#Topic/vaccines_industry_government_policy> # Vaccines industry--Government policy
    a schema:Intangible ;
    schema:name "Vaccines industry--Government policy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/144396839#Topic/vaccines_prices_government_policy> # Vaccines--Prices--Government policy
    a schema:Intangible ;
    schema:name "Vaccines--Prices--Government policy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/144396839#Topic/vaccines_research_economic_aspects> # Vaccines--Research--Economic aspects
    a schema:Intangible ;
    schema:name "Vaccines--Research--Economic aspects"@en ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.